Media Relations News Releases Year: - Any -201820172016 Items per page 102550 Jan 31, 2018 Summary ToggleNovartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah™ in children, young adults with r/r ALL Dec 10, 2017 Summary TogglePrimary analysis results from Novartis pivotal JULIET trial show Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer Nov 30, 2017 Summary ToggleNovartis’ Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients Nov 29, 2017 Summary ToggleNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab (AMG334) in migraine prevention Nov 10, 2017 Summary ToggleNovartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants Nov 10, 2017 Summary ToggleNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Nov 7, 2017 Summary ToggleNovartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage Nov 6, 2017 Summary ToggleNovartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years Oct 30, 2017 Summary ToggleNovartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA Oct 28, 2017 Summary ToggleNovartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a Pagination First page First Previous page Previous … Page 3 Current page 4 Page 5 Page 6 … Next page Next Last page Last
